Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma
Multiple Myeloma
About this trial
This is an interventional treatment trial for Multiple Myeloma focused on measuring Multiple Myeloma, Thalidomide, Anti-Angiogenesis
Eligibility Criteria
Inclusion Criteria: All patients must have a confirmed diagnosis of previously treated, active multiple myeloma Myeloma protein should be evident from which to evaluate response Must be 18 years of age or older. Women of childbearing age and fertile men must use a medically acceptable means of birth control while on study and for 6 months thereafter. Patients must sign an informed consent to participate in this study, and be fully aware of the known teratogenic potential of this drug Patients must have a total white blood cell count of 2,000 K/microliters. Patients may be anemic or thrombocytopenic provided this is felt to be due to extensive marrow involvement with myeloma Patients must have adequate liver function as demonstrated by a direct bilirubin of < or = 2.0 mg/dL. Exclusion Criteria: Patients must not have an active infection requiring parenteral antibiotics No other concurrent therapy for myeloma is permitted while on Thalidomide
Sites / Locations
- University of Arkansas for Medical Sciences/MIRT